ArticleClinical and experimental medicine2025
SPOP-dependent destabilization of SYT12 in a GSK-3β-dependent manner in papillary thyroid cancer cells.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Synaptotagmin 12 (SYT12), a protein found to be upregulated in papillary thyroid cancer (PTC), has emerged as a potential biomarker for this malignancy. However, the mechanisms governing its expression remain poorly understood. In this study, we identify SYT12 as a novel substrate of SPOP, an adaptor of the Cullin 3 E3 ubiquitin ligase complex. SPOP binds to SYT12 and mediates SYT12's K48-linked polyubiquitination and subsequent proteasomal degradation. This interaction is dependent on the degron motif within SYT12, and deletion or mutation of the degron significantly impairs SPOP binding and stabilizes SYT12. We further demonstrate that GSK-3β-mediated phosphorylation of the degron is essential for SPOP recognition. Pharmacological inhibition of GSK-3β disrupts the SPOP-SYT12 interaction and increases SYT12 protein levels. Functionally, the SPOP-SYT12 axis modulates PTC cell viability and proliferation. Collectively, these findings uncover a novel regulatory mechanism of SYT12 expression and suggest that targeting the SPOP-SYT12 pathway may represent a promising therapeutic strategy for PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.